Online citations, reference lists, and bibliographies.

Outcomes Of HPV-related Oropharyngeal Cancer Patients Treated By Radiotherapy Alone Using Altered Fractionation.

B O'Sullivan, Shao Hui Huang, Bayardo Perez-Ordóñez, Christine Massey, Lillian L. Siu, Ilan Weinreb, Andrew Hope, John Kim, Andrew J S Bayley, Bernard Cummings, Jolie Ringash, Laura A. Dawson, B C John Cho, Eric Chen, Jonathan Irish, Ralph W. Gilbert, Angela Hui, Fei-fei Liu, Helen Zhao, John N. Waldron, Wei Xu
Published 2012 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To report outcome of HPV-related [HPV(+)] oropharyngeal cancer (OPC) managed predominantly by altered-fractionation radiotherapy-alone (RT-alone). METHODS OPCs treated with RT-alone (n = 207) or chemoradiotherapy (CRT) (n = 151) from 2001 to 2008 were included. Overall survival (OS), local (LC), regional (RC) and distant (DC) control were compared for HPV(+) vs. HPV-unrelated [HPV(-)], by RT-alone vs. CRT, and by smoking pack-years (≤ 10 vs. >10). Multivariate analysis identified predictors. RESULTS HPV(+) (n = 277) had better OS (81% vs. 44%), LC (93% vs. 76%), RC (94% vs. 79%) (all p < 0.01) but similar DC (89% vs. 86%, p = 0.87) vs. HPV(-) (n = 81). HPV(+) stage IV CRT (n = 125) had better OS (89% vs. 70%, p < 0.01), but similar LC (93% vs. 90%, p = 0.41), RC (94% vs. 90%, p = 0.31) and DC (90% vs. 83%, p = 0.22) vs. RT-alone (n = 96). Both HPV(+) RT-alone (n = 37) and CRT (n = 67) stage IV minimal smokers had favorable OS (86% vs. 88%, p = 0.45), LC (95% vs. 92%, p = 0.52), RC (97% vs. 93%, p = 0.22), and DC (92% vs. 86%, p = 0.37). RT-alone and heavy-smoking were independent predictors for lower OS but not CSS in multivariate analysis. CONCLUSIONS Overall, HPV(+) RT-alone stage IV demonstrated lower survival but comparable disease control vs. CRT, but no difference was apparent among minimal smokers.
This paper references
10.1002/sim.2655
Analysing and interpreting competing risk data.
Melania Pintilie (2007)
National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010.
Konstantinos Markou (2011)
10.1093/annonc/mdr006
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.
Marshall R. Posner (2011)
10.1016/j.radonc.2011.09.010
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Kasper Toustrup (2012)
10.1016/j.ijrobp.2009.10.050
Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome.
Allen M Chen (2011)
10.1002/lary.20593
Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas.
Jos M. J. A. A. Straetmans (2009)
10.1186/1758-3284-2-15
Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)
Farshid Dayyani (2010)
10.1016/0360-3016(95)00060-C
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
James D. Cox (1995)
10.1158/1078-0432.CCR-09-3185
Bcl2 and Human Papilloma Virus 16 as Predictors of Outcome following Concurrent Chemoradiation for Advanced Oropharyngeal Cancer
Anthony C Nichols (2010)
10.1002/cncr.23742
Examining the association between socioeconomic status and potential human papillomavirus-associated cancers.
Vicki B. Benard (2008)
10.1016/j.radonc.2011.02.010
The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.
Pernille Lassen (2011)
10.1056/NEJMoa0912217
Human papillomavirus and survival of patients with oropharyngeal cancer.
K Kian Ang (2010)
10.1200/JCO.2009.23.1670
Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma.
Wei Shi (2009)
10.1016/0895-4356(95)00048-8
Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates.
Peter Peduzzi (1995)
10.1200/JCO.2007.14.8841
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.
Mitchell Machtay (2008)
Clinical trials. Broadcast: RTOG 0522
Kina Ang (2007)
10.1002/IJC.22851
Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.
Camille C R Ragin (2007)
10.1016/S1470-2045(09)70384-5
Optimising the therapeutic ratio in head and neck cancer.
June Corry (2010)
10.1093/jnci/djn011
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Carole Fakhry (2008)
10.1016/j.ijrobp.2008.12.088
Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status.
Carlo Fallai (2009)
10.1200/JCO.2010.29.2904
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Danny Rischin (2010)
10.1093/jnci/92.9.709
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.
Maura L. Gillison (2000)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
Mahul B. Amin (2002)
10.1016/j.radonc.2008.02.014
A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer.
John W. F. Waldron (2008)
10.1016/S0140-6736(06)69121-6
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
Jean Bourhis (2006)
10.1016/j.radonc.2009.10.008
HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
Pernille Lassen (2010)
10.1200/JCO.2005.02.105
Preliminary data release for randomized clinical trials of noninferiority: a new proposal.
Edward L. Korn (2005)
10.1016/j.ijrobp.2010.08.031
Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy.
Shao Hui Huang (2012)
10.1016/j.radonc.2010.04.022
The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome.
Pernille Lassen (2010)
10.1016/j.oraloncology.2009.11.004
Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer.
Gypsyamber D’souza (2010)
10.1586/era.10.6
Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations
Mónica Flores Ramos (2010)
10.1002/1097-0215(20000520)89:3<300::AID-IJC14>3.0.CO;2-G
Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival.
Hanna Mellin (2000)
10.1002/1097-0142(20010815)92:4<805::aid-cncr1386>3.0.co;2-9
Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma.
Katja Lindel (2001)
10.1200/JCO.2004.00.3335
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.
Paul Maurice Weinberger (2006)
10.1200/JCO.2008.20.2853
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
Pernille Lassen (2009)
Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma--relation to radiotherapy response and survival.
Signe Friesland (2001)
10.1200/JCO.2009.27.4498
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.
Lester J. Peters (2010)
10.1016/j.radonc.2010.03.015
Point-of-care outcome assessment in the cancer clinic: audit of data quality.
Karen W Y Wong (2010)



This paper is referenced by
10.1002/hed.23610
Comparison of functional outcomes and quality of life between transoral surgery and definitive chemoradiotherapy for oropharyngeal cancer.
Allen M Chen (2015)
10.3892/ol.2017.5844
Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.
Benedikt Kramer (2017)
10.1016/j.ejmp.2020.01.027
User-controlled pipelines for feature integration and head and neck radiation therapy outcome predictions.
Mattea L Welch (2020)
10.1007/978-3-319-42909-0_10
Treatment of Viral-Associated HNC (OPC and NPC)
Shao Hui Huang (2017)
10.1007/978-3-319-43580-0_12
Optimizing Radiotherapy in HPV-Associated Oropharyngeal Cancer Patients.
Johannes A. Langendijk (2017)
10.1007/s10147-019-01394-1
Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma
Yoshifumi Yamamoto (2019)
10.1002/cncr.30449
Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials From a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
Julie E Bauman (2017)
10.1007/s40136-018-0214-4
Surgery- vs Radiation-Based Therapy for p16+/HPV-Related Oropharyngeal Cancers
Kathy Rock (2018)
10.1007/978-3-030-32316-5_23
Deintensification of Treatment for HPV-Associated Cancers of the Oropharynx
Susan Y. Wu (2020)
10.1016/j.jcv.2014.06.019
Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer.
Sung Ho Um (2014)
10.3390/cancers8040041
HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies
Rüveyda Dok (2016)
10.1002/hed.25959
Reply to "Do not de-escalate oncology care in oropharyngeal cancer routinely".
Taru Ilmarinen (2019)
10.1177/107327481602300302
Management of Oropharyngeal Cancer in the HPV Era.
Arash O. Naghavi (2016)
10.2217/fon-2016-0073
Induction chemotherapy for head and neck cancer: is there still a role?
Roger Ove (2016)
10.5505/tjo.2019.2079
Importance of Hpv Positivity in Squamous Cell Head and Neck Cancer
Branislav Jeremić (2019)
10.1007/s12094-013-1074-5
Oropharyngeal cancer related to Human Papilloma Virus: incidence and prognosis in Madrid, Spain
Laura Cerezo (2013)
10.1007/s00106-020-00900-6
Rolle der Chirurgie und Salvage-Chirurgie in der Ära HPV-assoziierter Oropharynxkarzinome
Timon Hussain (2020)
10.18632/oncotarget.12086
Impact of label-free technologies in head and neck cancer circulating tumour cells
Arutha Kulasinghe (2016)
10.1002/hed.25593
De‐escalation of post‐treatment surveillance in oropharyngeal cancer
Taru Ilmarinen (2019)
10.1002/hed.25336
Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus‐associated oropharyngeal squamous cell carcinoma
Peter G Hawkins (2019)
10.1016/j.ijrobp.2013.08.049
Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status.
Shao Hui Huang (2013)
10.1007/978-3-319-21100-8
Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer
Daniel L. Miller (2015)
10.1016/j.radonc.2015.09.002
Modulation of therapeutic sensitivity by human papillomavirus.
Adam D. Swick (2015)
10.1002/hed.24285
Cervical nodal metastases from head and neck squamous cell carcinoma: MRI criteria for treatment assessment.
Ann D. King (2016)
10.1007/s00432-017-2553-9
Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status
Natalie M Lowe (2017)
10.1002/ijc.27956
Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma.
Angela M. Hong (2013)
The role of high-risk human papillomavirus in periocular cancers
Amir H Afrogheh (2018)
10.1007/978-981-15-3188-0_10
PET in the Diagnosis of Head and Neck Cancer
Tetsuro Sekine (2020)
10.1001/jamaoto.2015.136
Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Samuel J Trosman (2015)
10.1007/978-3-319-96809-4_4
Head and Neck Cancers
Daniel M. Trifiletti (2016)
10.1002/cncr.29782
Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
Jessica M. Frakes (2016)
10.17116/otorino201681172-77
[The clinical aspects of HPV-positive cancer of the oral cavity and oropharynx].
O Yu Dvoryaninova (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar